Shortly after securing the permission from World Health Organization and securing the rights to manufacture "Antiflu" to combat H1N1 virus (Swine flu) that has assumed the status of "pan epidemic", Indian drug manufacturer Cipla Ltd has offered USA to supply its generic version of Roche's Tamiflu, if required by the country. This statement has been officially confirmed by the chairman of Cipla Ltd. at a press-conference.
H1N1 virus (Swine flu) originated from Mexico and spread like wild-fire across the globe claiming many fatalities and earned the status of "pan epidemic" in June 2009.
During the official launch of the drug "Antiflu" in the market YK Hamied, Managing Director of Cipla Ltd at a media briefing remarked that there is an apparent shortage of H1N1 drug in US market.
YK Hamied added that an olive leaf is being offered to USA to overcome this shortage and puts the ball in their court.
He added that if the situation warranted Cipla had the necessary infrastructure and the capacity to manufacture 2 million doses of Oseltamivir monthly.
By exporting the drug to numerous countries across the globe in Latin America, Africa, certain nations in West Asia and South-East Asia, Cipla has earned revenue worth more than 10 millions US dollars.
The managing director added that on account of Patents Protection granted for Roche's Tamiflu, both US and Europe regulatory bodies have not permitted Cipla to sell its generic version in these two geographies.
Also at the same time, in India, Cipla has already supplied approximately 2 million capsules to the government to tackle H1N1 virus.
Cipla's Oseltamivir brand named as Antiflu, will be priced at Rs 475/- for 10 capsules. Shortly, 75 ml syrup is also expected to be similarly priced and will be sold only at select pharamacies in India possessing Schedule X liscence.